• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>2010 Proceedings of Technology Management for Global Economic Growth >Intellectual Property and information on Intellectual Property Rights management of Japanese pharmaceutical companies in MA
【24h】

Intellectual Property and information on Intellectual Property Rights management of Japanese pharmaceutical companies in MA

机译：并购中日本制药公司的知识产权和知识产权管理信息

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is important for a pharmaceutical company after a Merger and Acquisition (M&A) to intentionally manage the Intellectual Property (IP) and information on Intellectual Property Rights (IPRs) of the two companies involved in the M&A. We examined IP management in two cases of M&A of Japanese pharmaceutical companies using IP management indices including the proportion of patent applications for which a request for examination are filed. Also, we interviewed the IP management departments of pharmaceutical companies regarding IP and IPR information management. As a result, it was demonstrated that, in the cases of M&A of two new-drug companies 1) The ways of managing IP protection of the companies before M&A are different with each other or similar in each IP management indices. 2) The ways of managing information on IPR in the new-drug companies before M&A could be blended with little difficulties because of their similarity with one another.
机译：在并购（M＆A）之后，对于制药公司而言，有意管理参与并购的两家公司的知识产权（IP）和有关知识产权的信息（IPR）至关重要。我们在两个日本制药公司的并购案例中使用IP管理指标（包括已提出审查请求的专利申请的比例）对IP管理进行了审查。此外，我们还采访了制药公司的IP管理部门，以了解IP和IPR信息管理。结果表明，在两家新药公司的并购案例中：1）并购前两家公司的知识产权保护管理方式在每个IP管理指标上彼此不同或相似。 2）在新药企业并购之前管理知识产权信息的方式可以很容易地混合在一起，因为它们彼此相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号